Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study
- PMID: 30103321
- DOI: 10.3233/JAD-180232
Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study
Abstract
Background: Biomarkers of neurodegeneration play a major role in the diagnosis of Alzheimer's disease (AD). Information on both amyloid-β accumulation, e.g., from amyloid positron emission tomography (PET), and downstream neuronal injury, e.g., from 18F-fluorodeoxyglucose (FDG) PET, would ideally be obtained in a single procedure.
Objective: On the basis that the parallelism between brain perfusion and glucose metabolism is well documented, the objective of this work is to evaluate whether brain perfusion estimated in a dual-point protocol of 18F-florbetaben (FBB) PET can be a surrogate of FDG PET in appropriate use criteria (AUC) for amyloid PET.
Methods: This study included 47 patients fulfilling international AUC for amyloid PET. FDG PET, early FBB (pFBB) PET (0-10 min post injection), and standard FBB (sFBB) PET (90-110 min post injection) scans were acquired. Results of clinical subjective reports and of quantitative region of interest (ROI)-based analyses were compared between procedures using statistical techniques such as Pearson's correlation coefficients and t-tests.
Results: pFBB and FDG visual reports on the 47 patients showed good agreement (k > 0.74); ROI quantitative analysis indicated that both data modalities are highly correlated; and the t-test analysis does not reject the null hypothesis that data from pFBB and FDG examinations comes from independent random samples from normal distributions with equal means and variances.
Conclusions: A good agreement was found between pFBB and FDG data as obtained by subjective visual and quantitative analyses. Dual-point FBB PET scans could offer complementary information (similar to that from FDG PET and FBB PET) in a single procedure, considering pFBB as a surrogate of FDG.
Keywords: Alzheimer’s disease; FDG PET; amyloid PET; appropriate use criteria; brain perfusion; brain rCBF; brain rCMRglc; florbetaben PET; mild cognitive impairment; quantitative analysis.
Similar articles
-
Early-Phase 18F-Florbetaben PET as an Alternative Modality for 18F-FDG PET.Clin Nucl Med. 2020 Jan;45(1):e8-e14. doi: 10.1097/RLU.0000000000002768. Clin Nucl Med. 2020. PMID: 31524679 Clinical Trial.
-
Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases.Neuroimage Clin. 2016 Oct 8;14:77-86. doi: 10.1016/j.nicl.2016.10.005. eCollection 2017. Neuroimage Clin. 2016. PMID: 28138429 Free PMC article.
-
Evaluation of early-phase 18F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with 18F-FDG PET at group and single patient level.J Alzheimers Dis. 2025 Jul;106(1):304-316. doi: 10.1177/13872877251340380. Epub 2025 May 8. J Alzheimers Dis. 2025. PMID: 40340729 Free PMC article.
-
[(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment.CNS Drugs. 2015 Jul;29(7):605-13. doi: 10.1007/s40263-015-0258-7. CNS Drugs. 2015. PMID: 26175116 Review.
-
Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.Rev Esp Med Nucl Imagen Mol. 2015 Sep-Oct;34(5):303-13. doi: 10.1016/j.remn.2015.03.002. Epub 2015 Jun 20. Rev Esp Med Nucl Imagen Mol. 2015. PMID: 26099942 English, Spanish.
Cited by
-
Correlation of Early-Phase F-18 Florapronal PET with F-18 FDG PET in Alzheimer's Disease and Normal Brain.Nucl Med Mol Imaging. 2019 Oct;53(5):328-333. doi: 10.1007/s13139-019-00612-y. Epub 2019 Sep 11. Nucl Med Mol Imaging. 2019. PMID: 31723362 Free PMC article.
-
Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated.Sci Rep. 2021 Jun 10;11(1):12297. doi: 10.1038/s41598-021-91891-z. Sci Rep. 2021. PMID: 34112926 Free PMC article.
-
Feasibility evaluation of middle-phase 18F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment.Quant Imaging Med Surg. 2023 Aug 1;13(8):4806-4815. doi: 10.21037/qims-23-58. Epub 2023 Jun 14. Quant Imaging Med Surg. 2023. PMID: 37581034 Free PMC article.
-
High Correlation of Static First-Minute-Frame (FMF) PET Imaging after 18F-Labeled Amyloid Tracer Injection with [18F]FDG PET Imaging.Sensors (Basel). 2021 Jul 30;21(15):5182. doi: 10.3390/s21155182. Sensors (Basel). 2021. PMID: 34372416 Free PMC article.
-
Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria.Medicine (Baltimore). 2019 Jul;98(29):e16509. doi: 10.1097/MD.0000000000016509. Medicine (Baltimore). 2019. PMID: 31335725 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources